Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 best AI driven biotech stocks to invest in.

On June 3, enrollment for the Phase 1/2 ACHIEVE trial’s registrational expansion cohort, which evaluates z-basivarsen (DYNE-101) in individuals with myotonic dystrophy type 1 (DM1), has concluded, according to a statement from Dyne Therapeutics Inc. (NASDAQ:DYN). The business sees this as a significant step in developing what it thinks may be a best-in-class medication meant to address the disease’s wide range of symptoms.

Tonhom1009/Shutterstock.com

According to Chief Medical Officer Doug Kerr, data from the cohort is anticipated in the first quarter of the next year and may show significant improvements in myotonia coupled with favorable trends in important functional metrics. Kerr stated:

“Completing enrollment in the registrational expansion cohort of ACHIEVE is a critical milestone as we advance a potentially best-in-class therapy designed to address the multi-system nature of DM1. With data from this cohort expected in the first quarter of next year, we believe we are well positioned to show a significant improvement in myotonia and trends on important functional outcomes to support a potential submission for U.S. Accelerated Approval. We expect that the strong interest we have seen in z-basivarsen will support enrollment in the ongoing confirmatory Phase 3 HARMONIA trial.”

Dyne Therapeutics Inc. (NASDAQ:DYN) is a biotechnology company that formulates life-transforming targeted therapeutics for individuals with genetically driven neuromuscular diseases. It uses its FORCE platform to identify the root cause of a condition and currently has a strong pipeline of clinical and preclinical programs.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.